Biotech Pioneer Appointed to Growing UK Life Science Company

Q Chip Ltd has announced the appointment of Ken Powell as Executive Chairman.

With a career spanning more than three decades as a senior researcher and manager in the pharmaceutical sector Ken Powell is widely acknowledged by the industry as one of its pioneers. His previous positions include CEO of Arrow Therapeutics, Head of Antiviral Research and Head of Biology at the Wellcome Foundation and Professor of Virology and Cell Biology at the Wolfson Institute for Biomedical Research at University College, London.

Ken Powell has an enviable record in founding and building life science start-ups. During his period of employment with the Wolfson Institute he helped establish Inpharmatica, now part of Galapagos NV and Ark Therapeutics which listed on the London Stock Exchange’s main market in March 2004. Ken currently serves as the Head of Arrow Therapeutics, which he founded in 1998 and was acquired by Astra-Zeneca PLC for $150 million in February 2007.

Commenting on his appointment Ken Powell said “I have accepted the role of Executive Chairman of Q Chip for the simple reason I am excited by its prospects. It has undertaken some very exciting research, which provides the foundations for a strong pipeline of applications and products. The product opportunities presented by Q Chip’s technology will offer cost effective solutions to some of the most pressing issues in the biotech industry. I am particularly delighted to have the opportunity to assist Q Chip in the development of its MicroPlantTM drug delivery technology and expanding the commercial reach of its unique ReaX™ range of easy to use, beaded molecular reagents.”